Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 4
2007 5
2008 2
2009 2
2010 3
2011 4
2012 2
2013 7
2014 10
2015 8
2016 8
2017 8
2018 10
2019 5
2020 9
2021 14
2022 11
2023 5
2024 9
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group. Finkel RS, et al. N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752. N Engl J Med. 2017. PMID: 29091570 Free article. Clinical Trial.
Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L; FIREFISH Working Group. Baranello G, et al. N Engl J Med. 2021 Mar 11;384(10):915-923. doi: 10.1056/NEJMoa2009965. Epub 2021 Feb 24. N Engl J Med. 2021. PMID: 33626251 Clinical Trial.
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Servais L, Xiong H, Zanoteli E, Baranello G, Bruno C, Day JW, Deconinck N, Klein A, Mercuri E, Vlodavets D, Wang Y, Dodman A, El-Khairi M, Gorni K, Jaber B, Kletzl H, Gaki E, Fontoura P, Darras BT; FIREFISH Study Group. Masson R, et al. Lancet Neurol. 2022 Dec;21(12):1110-1119. doi: 10.1016/S1474-4422(22)00339-8. Epub 2022 Oct 14. Lancet Neurol. 2022. PMID: 36244364 Clinical Trial.
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L; FIREFISH Working Group. Darras BT, et al. N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047. N Engl J Med. 2021. PMID: 34320287
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Staunton H, Yeung WY, Martin C, Fontoura P, Day JW; SUNFISH Study Group. Mercuri E, et al. Lancet Neurol. 2022 Jan;21(1):42-52. doi: 10.1016/S1474-4422(21)00367-7. Lancet Neurol. 2022. PMID: 34942136
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.
Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C. Martello M, et al. Among authors: tacchetti p. Blood Cancer J. 2024 Nov 28;14(1):208. doi: 10.1038/s41408-024-01185-6. Blood Cancer J. 2024. PMID: 39609411 Free PMC article.
Imaging in multiple myeloma: How? When?
Zamagni E, Tacchetti P, Cavo M. Zamagni E, et al. Among authors: tacchetti p. Blood. 2019 Feb 14;133(7):644-651. doi: 10.1182/blood-2018-08-825356. Epub 2018 Dec 26. Blood. 2019. PMID: 30587527 Free article. Review.
Multiple myeloma: disease response assessment.
Zamagni E, Tacchetti P, Terragna C, Cavo M. Zamagni E, et al. Among authors: tacchetti p. Expert Rev Hematol. 2016 Sep;9(9):831-7. doi: 10.1080/17474086.2016.1212654. Epub 2016 Jul 25. Expert Rev Hematol. 2016. PMID: 27409577 Review.
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.
Mancuso K, Mina R, Rocchi S, Antonioli E, Petrucci MT, Fazio F, Gozzetti A, Salvini M, Cartia CS, Bertuglia G, Patriarca F, Dalla Palma AB, Barbato S, De Cicco G, Bigi F, Favero E, Tacchetti P, Pantani L, Rizzello I, Puppi M, Talarico M, Solli V, Kanapari A, Cavo M, Zamagni E. Mancuso K, et al. Among authors: tacchetti p. Cancer Med. 2024 Nov;13(22):e70266. doi: 10.1002/cam4.70266. Cancer Med. 2024. PMID: 39587728 Free PMC article.
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.
Talarico M, Barbato S, Cattabriga A, Sacchetti I, Manzato E, Restuccia R, Masci S, Bigi F, Puppi M, Iezza M, Rizzello I, Mancuso K, Pantani L, Tacchetti P, Nanni C, Cavo M, Zamagni E. Talarico M, et al. Among authors: tacchetti p. J Bone Oncol. 2025 Feb 28;51:100669. doi: 10.1016/j.jbo.2025.100669. eCollection 2025 Apr. J Bone Oncol. 2025. PMID: 40124904 Free PMC article. Review.
119 results